{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:57:59Z","timestamp":1793059079001,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clindermatol.2026.09.018","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:39:30Z","timestamp":1790177970000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["GLP-1 receptor agonists in dermatology: Prescribing frameworks, access, and the emerging pipeline"],"prefix":"10.1016","author":[{"given":"Alina G.","family":"Bridges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.09.018_bib0001","unstructured":"U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). 46th ed. Silver Spring, MD: U.S. Food and Drug Administration; 2026. Accessed October 1, 2026. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/approved-drug-products-therapeutic-equivalence-evaluations-orange-book"},{"key":"10.1016\/j.clindermatol.2026.09.018_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2026.01.088","article-title":"JAAD CME Part 1: Mechanism of action of GLP-1 receptor agonists and potential pathways in skin health","author":"Narla","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.018_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2025.12.116","article-title":"JAAD CME Part 2: Clinical evidence and safety considerations for GLP-1 receptor agonists in dermatology","author":"Narla","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.clindermatol.2026.09.018_bib0004","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamadermatol.2026.0859","article-title":"The National Psoriasis Foundation primer on GLP-1 receptor agonists in psoriasis: a review","volume":"162","author":"Sheth","year":"2026","journal-title":"JAMA Dermatol"},{"issue":"20","key":"10.1016\/j.clindermatol.2026.09.018_bib0005","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1001\/jama.2025.15841","article-title":"Medicare Part D coverage and costs for glucagon-like peptide-1 receptor agonists","volume":"334","author":"Klebanoff","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2026.09.018_bib0006","unstructured":"American Academy of Dermatology. Position statement: dermatologic off-label use of therapies and treatments; 2022."},{"issue":"7","key":"10.1016\/j.clindermatol.2026.09.018_bib0007","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamadermatol.2026.1753","article-title":"Ixekizumab with or without tirzepatide in adults with psoriasis and overweight or obesity: a phase 3b randomized clinical trial","volume":"162","author":"Lebwohl","year":"2026","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.018_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1744308","article-title":"Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities","volume":"17","author":"Ciancio","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2026.09.018_bib0009","doi-asserted-by":"crossref","unstructured":"Haberman RH, Rice AL, Chen K, et al. Glucagon-like peptide-1 receptor agonist therapy is associated with improvement in psoriatic arthritis\u2013related and metabolic outcomes: a retrospective analysis of two cohorts. Arthritis Rheumatol FLAG, ed. 2026, April 6. doi:10.1002\/art.70170: Epub ahead of print. PMID: 41940492; PMCID: PMC13154331.]","DOI":"10.1002\/art.70170"},{"issue":"3","key":"10.1016\/j.clindermatol.2026.09.018_bib0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41584-025-01326-6","article-title":"The obesity\u2013inflammation axis in psoriatic disease: mechanisms and therapeutic strategies","volume":"22","author":"Haberman","year":"2026","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clindermatol.2026.09.018_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/art.70134","article-title":"Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial","author":"Merola","year":"2026","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.clindermatol.2026.09.018_bib0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.drudis.2018.07.005","article-title":"Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway","volume":"24","author":"Salminen","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.clindermatol.2026.09.018_bib0013","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/bs.pmbts.2024.03.024","article-title":"Approaches of pre-clinical and clinical trials of repurposed drug","volume":"205","author":"Israr","year":"2024","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.clindermatol.2026.09.018_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174569","article-title":"Repurposing old molecules for new indications: defining pillars of success from lessons in the past","volume":"912","author":"Mittal","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.1016\/j.clindermatol.2026.09.018_bib0015","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.clindermatol.2026.09.018_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2024.09.002","article-title":"The American Board of Obesity Medicine: a pathway to the provision of competent obesity medicine care","volume":"54","author":"Johnson-Rabbett","year":"2025","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"10.1016\/j.clindermatol.2026.09.018_bib0017","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/oby.70013","article-title":"An update on the American Board of Obesity Medicine (ABOM): 2017-2024","volume":"33","author":"Johnson-Rabbett","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.clindermatol.2026.09.018_bib0018","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000001221","article-title":"Implementation of obesity science into clinical practice: a scientific statement from the American Heart Association","volume":"150","author":"Laddu","year":"2024","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.clindermatol.2026.09.018_bib0019","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jama.2025.14392","article-title":"New molecules and indications for GLP-1 medicines","volume":"334","author":"Gonzalez-Rellan","year":"2025","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.clindermatol.2026.09.018_bib0020","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2025.05.024","article-title":"2025 concise clinical guidance: an ACC expert consensus statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology solution set oversight committee","volume":"86","author":"Gilbert","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.clindermatol.2026.09.018_bib0021","first-page":"145","article-title":"Management of obesity: office-based strategies","volume":"110","author":"Keating","year":"2024","journal-title":"Am Fam Physician"},{"issue":"2","key":"10.1016\/j.clindermatol.2026.09.018_bib0022","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2337\/dci24-0091","article-title":"Compounded GLP-1 and dual GIP\/GLP-1 receptor agonists: a statement from the American Diabetes Association","volume":"48","author":"Neumiller","year":"2025","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.clindermatol.2026.09.018_bib0023","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.eprac.2025.07.017","article-title":"American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease\u20142025 update","volume":"31","author":"Nadolsky","year":"2025","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.clindermatol.2026.09.018_bib0024","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1177\/10600280261421979","article-title":"Compounded semaglutide and tirzepatide products use unique formulations but efficacy and safety largely unknown","volume":"60","author":"Belcourt","year":"2026","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.clindermatol.2026.09.018_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2025.103314","article-title":"Compounded incretins in clinical practice: an opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy","volume":"19","author":"Courtney","year":"2025","journal-title":"Diabetes Metab Syndr"},{"issue":"9","key":"10.1016\/j.clindermatol.2026.09.018_bib0026","doi-asserted-by":"crossref","first-page":"480","DOI":"10.37765\/ajmc.2025.89787","article-title":"Navigating compounded semaglutide: what health care providers need to know","volume":"31","author":"Liu","year":"2025","journal-title":"Am J Manag Care"},{"issue":"10","key":"10.1016\/j.clindermatol.2026.09.018_bib0027","first-page":"1029","article-title":"Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes","volume":"31","author":"Wu","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.clindermatol.2026.09.018_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.55222","article-title":"Factors associated with semaglutide initiation among adults with obesity","volume":"8","author":"Podolsky","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.clindermatol.2026.09.018_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2025.0905","article-title":"Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum"},{"issue":"8","key":"10.1016\/j.clindermatol.2026.09.018_bib0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.29842","article-title":"Coverage and prior authorization policies for semaglutide and tirzepatide in Medicare Part D plans","volume":"8","author":"Liu","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.clindermatol.2026.09.018_bib0031","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11606-023-08416-9","article-title":"Medicare Part D coverage of anti-obesity medications: a call for forward-looking policy reform","volume":"39","author":"Hernandez","year":"2024","journal-title":"J Gen Intern Med"},{"issue":"3","key":"10.1016\/j.clindermatol.2026.09.018_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2008","article-title":"Older adults\u2019 views on insurance coverage for weight management medications","volume":"8","author":"Oshman","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.clindermatol.2026.09.018_bib0033","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1007\/s11606-026-10408-4","article-title":"Trends in GLP-1 receptor agonist and SGLT2-inhibitor utilization and expenditure between 2017 and 2023: demographic, income, and insurance associations","volume":"41","author":"Jacobs","year":"2026","journal-title":"J Gen Intern Med"},{"issue":"20","key":"10.1016\/j.clindermatol.2026.09.018_bib0034","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1001\/jama.2024.17275","article-title":"Strategies to help patients navigate high prescription drug costs","volume":"332","author":"Lalani","year":"2024","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.clindermatol.2026.09.018_bib0035","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMp2303535","article-title":"Patient-assistance programs, kickbacks, and the courts","volume":"388","author":"Elberg","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clindermatol.2026.09.018_bib0036","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/1744666X.2026.2665732","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in dermatology: cutaneous adverse events and emerging efficacy in inflammatory skin diseases","volume":"22","author":"Ho","year":"2026","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.clindermatol.2026.09.018_bib0037","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00403-024-02969-3","article-title":"Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature","volume":"316","author":"Salazar","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.clindermatol.2026.09.018_bib0038","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/endrev\/bnaf036","article-title":"Novel GLP-1\u2013based medications for type 2 diabetes and obesity","volume":"47","author":"Son","year":"2026","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clindermatol.2026.09.018_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2025.171380","article-title":"Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities","volume":"187","author":"Bailey","year":"2025","journal-title":"Peptides"},{"issue":"13","key":"10.1016\/j.clindermatol.2026.09.018_bib0040","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMra2500106","article-title":"GLP-1 receptor agonists","volume":"394","author":"Rosen","year":"2026","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clindermatol.2026.09.018_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.clindermatol.2026.09.018_bib0042","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/dom.70382","article-title":"Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: insights from meta-analysis of randomised controlled trials and real-world evidence","volume":"28","author":"Taj","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.clindermatol.2026.09.018_bib0043","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1007\/s00405-025-09406-9","article-title":"Off-label drugs in laryngology\u2014what should the doctor and the patient know about such therapies? A consensus statement of the European Laryngological Society","volume":"282","author":"Wierzbicka","year":"2025","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"10.1016\/j.clindermatol.2026.09.018_bib0044","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12875-022-01666-2","article-title":"Influence of data disclosures on physician decisions about off-label uses: findings from a qualitative study","volume":"23","author":"Chansky","year":"2022","journal-title":"BMC Prim Care"},{"issue":"6","key":"10.1016\/j.clindermatol.2026.09.018_bib0045","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMp2516086","article-title":"Using FDA law to threaten medical practice","volume":"394","author":"Grossman","year":"2026","journal-title":"N Engl J Med"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:33:02Z","timestamp":1791631982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X26002440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"alternative-id":["S0738081X26002440"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.018","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists in dermatology: Prescribing frameworks, access, and the emerging pipeline","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}